Upperton Completes New Development of GMP Manufacturing Facility
The goal for Upperton is to become fully operational by Q4 of 2023 for development and non-GMP manufacturing and a target start of GMP operations in January 2024.
Upperton Pharma Solutions has finished the construction of their new development and good manufacturing practices (GMP) manufacturing facility in Nottingham, UK, as of July 12, 2023.
According to the press release, the new building can house 10 new GMP manufacturing suites, quality control laboratories, and formulation development with pilot plant capabilities. Additionally, it is capable of handling highly potent and controlled drugs, clinical trial supplies, and support for early formulation development. There was a major investment in commercial scale equipment, offering powder blending, capsule filling, dry granulation processing, and tablet processing.
“We are delighted with the progress of our Nottingham facility since we first began on this journey in January 2023. This build completion is a significant milestone for us and represents our significant growth as a company,” said Nikki Whitfield, chief executive officer at Upperton in a press release. “By increasing the scale at which we can operate, we are looking forward to being able to offer our customers a smooth transition from early development to clinical trials and commercial manufacturing for low volume, niche products – all at one, single site, with established project teams.”
The goal for Upperton is to become fully operational by Q4 of 2023 for development and non-GMP manufacturing and a target start of GMP operations in January 2024.
Source: Upperton Pharma Solutions
